newsfilter
← Latest News
GlobeNewswire·

Cabaletta Bio Outlines Strategic Priorities and Anticipated Key Milestones for 2025

– Company plans to meet with the FDA to align on registrational trial designs in 1H25 based on emerging clinical profile of resecabtagene autoleucel (rese-cel, formerly referred to as CABA-201) and increased pace of